Effectiveness of the measles and rubella live attenuated vaccination for pediatric patients treated with not high dose corticosteroid - Effectiveness of the measles and rubella live attenuated vaccination for pediatric patients treated with not high dose corticosteroid

Ishii Taku0 sites0 target enrollmentStarted: April 22, 2019Last updated: October 17, 2023

Trial Snapshot

This study was discontinued because it has become difficult to enroll patients due to change in social conditions.

•1. Aged from 5 years old to under 15 years old
•2. Current treatment with steroids the dose of which satisfies all of the following
•2-1.Less than 1mg/kg/day or 2mg/kg/day
•2-2.Less than 20mg/day
•2-3.No increase in steroids more than 4 weeks or 28 days
•3. Patients of inoculation with MR vaccine once at a year old or over

•1. Current treatment with high dose immunosuppressive agents
•Definition of high dose immunosuppressive agents is as follows
•Salazosulfapyridine more than 40mg/kg/day
•Leflunomide more than 0.25mg/kg/day
•Methotrexate more than 15mg/m2/week
•Cyclosporine more than 2.5mg/kg/day
•Tacrolimus more than 0.06mg/kg/day
•Azathioprine more than 1mg/kg/day
•Cyclophosphamide more than 0.5mg/kg/day
•6-Mercaptopurine more than 1.5mg/kg/day
•2. Cases with side effect requiring treatment at the time of MR vaccination in the past
•3. Cases with febrile disease within 4 weeks prior to vaccination
•4. Cases receiving transfusion or administration of biological products within 3 months prior to vaccination
•5. Cases receiving other live attenuated vaccine within 4 weeks or 28 days
•6. Cases receiving inactivated vaccine within 6 days
•7. Cases diagnosed as primary immunodeficiency disease
•8. Cases likely to require treatment enhancement within 4 weeks after vaccination
•9. Cases in whom both of measles and rubella antibody titers were higher than criteria
•10. Cases living with a pregnant woman

Sponsor

Ishii Taku